

POST-TEST

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Acute Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following efficacy outcomes was reported with venetoclax and a hypomethylating agent in comparison to intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and no actionable mutations in the PARADIGM study?
 - a. Inferior overall response rate (ORR)
 - b. Similar ORRs
 - c. Numerical but nonsignificant increase in ORR
 - d. Significant increase in ORR**
2. Which of the following statements best describes overall survival (OS) outcomes with quizartinib in comparison to placebo, added to standard induction chemotherapy and consolidation and continued as a single agent for patients with newly diagnosed AML with a **FLT3-ITD mutation** in the Phase III QuANTUM-First study?
 - a. Median OS was not improved
 - b. A trend toward improvement in median OS was reported
 - c. Median OS was doubled**
 - d. Median OS was tripled
3. Which of the following statements best describes outcomes from the Phase III BMT-CTN 1506/MORPHO study of gilteritinib administered as maintenance therapy after hematopoietic stem cell transplant for patients with AML and **FLT3-ITD mutations**?
 - a. Maintenance gilteritinib benefitted all patients
 - b. Maintenance gilteritinib did not benefit any patients
 - c. Maintenance gilteritinib was beneficial to patients with detectable minimal residual disease after transplant**
 - d. Maintenance gilteritinib was beneficial to patients with certain co-occurring mutations
4. Which of the following statements best characterizes efficacy outcomes with olutasidenib or ivosidenib monotherapy for patients with relapsed/refractory (R/R) AML and IDH1 mutations?
 - a. Duration of complete remission is approximately the same between olutasidenib and ivosidenib
 - b. Duration of complete remission is longer for patients receiving olutasidenib**
 - c. Duration of complete remission is longer for patients receiving ivosidenib
5. Recently the FDA approved ziftomenib for R/R AML in which of the following patient populations?
 - a. Patients with KMT2A mutations
 - b. Patients with NPM1 mutations**
 - c. Patients with both KMT2A and NPM1 mutations
 - d. Patients with neither KMT2A nor NPM1 mutations